| For: | Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn’s disease. World J Gastroenterol 2009; 15(35): 4449-4452 [PMID: 19764100 DOI: 10.3748/wjg.15.4449] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i35/4449.htm |
| Number | Citing Articles |
| 1 |
Enrique Gómez, Maria Jose Torres, Cristobalina Mayorga, Miguel Blanca. Immunologic Evaluation of Drug Allergy. Allergy, Asthma & Immunology Research 2012; 4(5) doi: 10.4168/aair.2012.4.5.251
|
| 2 |
Maxine Gossell-Williams, Gabrielle McLaren, Rojay Clarke, Shenae Douglas, Devonne Gayle, Kerrian Guthrie. Rapid review of drug induced Stevens Johnson Syndrome case reports from 2003 to 2023: Trends among monoclonal antibodies and systemic immunosuppressant therapy. International Journal of Risk & Safety in Medicine 2025; 36(4) doi: 10.1177/09246479251368022
|
| 3 |
ID O’Neill, C Scully. Biologics in oral medicine: principles of use and practical considerations. Oral Diseases 2012; 18(6) doi: 10.1111/j.1601-0825.2012.01919.x
|
| 4 |
Daniel C. Baumgart, Ulrike Grittner, Andrea Steingräber, Marina Azzaro, Sandra Philipp. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients. Inflammatory Bowel Diseases 2011; 17(12) doi: 10.1002/ibd.21643
|
| 5 |
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2010; 19(4) doi: 10.1002/pds.1849
|
| 6 |
Inês Marques, Ana Lagos, Jorge Reis, António Pinto, Beatriz Neves. Reversible Henoch–Schönlein purpura complicating adalimumab therapy. Journal of Crohn's and Colitis 2012; 6(7) doi: 10.1016/j.crohns.2012.02.019
|
| 7 |
Dean Edwards, Eli Boritz, Edward W. Cowen, Ronald S. Brown. Erythema multiforme major following treatment with infliximab. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2013; 115(2) doi: 10.1016/j.oooo.2012.08.001
|
| 8 |
Houci Yang, Junjun Xu, Jiali Zhang, Xiaoyu Zhang, Chenghui Jin, Haibin Dai, Mingdong Yang. Research progress on potential high-risk drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1775888
|
| 9 |
Joana Torres, Sébastien Buche, Emmanuel Delaporte, Jean-Frédéric Colombel. Skin Side Effects of Inflammatory Bowel Disease Therapy. Inflammatory Bowel Diseases 2013; 19(5) doi: 10.1097/MIB.0b013e3182802c07
|
| 10 |
Yue Yin, Yuanyuan Wang, Jing Zhou, Yifei Xu, Jiangluyi Cai, Nan Yang, Yuxiong Jiang, Xiaomin She, Yuanting Zhi, Zhengkai Qu, Bo Yu, Jun Gu, Yuling Shi, Xilin Zhang. Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions. Drugs 2026; doi: 10.1007/s40265-026-02354-6
|
| 11 |
Debra F Eisenberg, Gregory W Daniel, Judith K Jones, Earl L Goehring, Peter M Wahl, Peter Winters, Jay Levin, Rhonda L Bohn. Validation of a claims‐based diagnostic code for Stevens–Johnson syndrome in a commercially insured population. Pharmacoepidemiology and Drug Safety 2012; 21(7) doi: 10.1002/pds.3276
|
| 12 |
Eccard da Silva Ricardo, Garbi Novaes Alice, Bernarda Donato Göttems Leila, Rita Carvalho Garbi Novaes Maria. Risk factors for, and treatment of, Stevens-Johnson syndrome and toxic epidermal necrolysis: Evidence from the literature. African Journal of Pharmacy and Pharmacology 2018; 12(4) doi: 10.5897/AJPP2017.4873
|
| 13 |
Elham Behrangi, Farzan Moodi, Alireza Jafarzadeh, Azadeh Goodarzi. Paradoxical and bimodal immune‐mediated dermatological side effects of TNF‐α inhibitors: A comprehensive review. Skin Research and Technology 2024; 30(5) doi: 10.1111/srt.13718
|
| 14 |
S. Bhadresha, A. J. Hughes, L. McMahon, S. Reeken, N. Natkunarajah. Fixed drug eruption secondary to adalimumab. Clinical and Experimental Dermatology 2021; 46(2) doi: 10.1111/ced.14400
|
| 15 |
Eleni A. Georgakopoulou, Crispian Scully. Orofacial adverse effects of biological agents. Journal of Investigative and Clinical Dentistry 2015; 6(4) doi: 10.1111/jicd.12102
|
| 16 |
Muhammad Ali Shazib, Kevin M. Byrd, Ajay S. Gulati. Diagnosis and Management of Oral Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition 2022; 74(1) doi: 10.1097/MPG.0000000000003302
|
| 17 |
Kenan Kherallah, Imran Ahmad, Anishka Bandara, Jacob Kattoula, Ivan Rodriguez, Scott Worswick. Adverse Cutaneous Reactions to Monoclonal Antibodies: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Erythema Multiforme, and Fixed Drug Eruption – A Systematic Review. Biomedicine Hub 2025; 10(1) doi: 10.1159/000545623
|
| 18 |
Souichi Shiratori, Hiroyuki Ohhigashi, Shinichi Ito, Kazuhiro Kudo, Maki Adachi, Toshiyuki Minamimoto, Junji Kato, Yasue Osai, Yutaka Tsutsumi, Takanori Teshima. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti‐CC chemokine receptor 4 antibody for the treatment of adult T‐cell leukaemia/lymphoma. Hematological Oncology 2017; 35(1) doi: 10.1002/hon.2242
|
| 19 |
Abraham Kwak, Sung Ae Kim, Hee Joung Choi. Toxic Epidermal Necrolysis complicating Infliximab therapy in Refractory Kawasaki disease. Keimyung Medical Journal 2020; 39(2) doi: 10.46308/kmj.2020.00094
|
| 20 |
Anna Yuan, Sook-Bin Woo. Adverse Drug Events in the Oral Cavity. Dermatologic Clinics 2020; 38(4) doi: 10.1016/j.det.2020.05.012
|
| 21 |
Jinan Q Mohammed, Zainab Mahmmod, Abdulsatar J Mathkhor. Adalimumab-Induced Erythema Multiforme in a Patient With Rheumatoid Arthritis: A Case Report. Cureus 2022; doi: 10.7759/cureus.21126
|
| 22 |
Břetislav Lipový, Jakub Holoubek. Current perspective on the role of TNFα inhibitors in treating patients with toxic epidermal necrolysis. Klinická farmakologie a farmacie 2016; 30(4) doi: 10.36290/far.2016.031
|
| 23 |
Miranda Muhvić-Urek, Marija Tomac-Stojmenović, Brankica Mijandrušić-Sinčić. Oral pathology in inflammatory bowel disease. World Journal of Gastroenterology 2016; 22(25): 5655-5667 doi: 10.3748/wjg.v22.i25.5655
|
| 24 |
Marta Ferran Farrés. Efectos secundarios cutáneos de los fármacos antagonistas del factor de necrosis tumoral α. Piel 2012; 27(10) doi: 10.1016/j.piel.2012.05.003
|
| 25 |
Julio Ramírez, M. Victoria Hernández, Javier Galve, Juan D. Cañete, Raimon Sanmartí. Morphea associated with the use of adalimumab: a case report and review of the literature. Modern Rheumatology 2012; 22(4) doi: 10.1007/s10165-011-0550-4
|
| 26 |
Julio Ramírez, M. Victoria Hernández, Javier Galve, Juan D. Cañete, Raimon Sanmartí. Morphea associated with the use of adalimumab: a case report and review of the literature. Modern Rheumatology 2012; 22(4) doi: 10.3109/s10165-011-0550-4
|
| 27 |
Hui Li, Feng Tian. Toxic Epidermal Necrolysis Because of Various Herpesviruses Infection After Accelerated Infliximab Induction in a Chinese Patient With Acute Severe Ulcerative Colitis. Inflammatory Bowel Diseases 2020; 26(5) doi: 10.1093/ibd/izaa034
|
| 28 |
Jenny Roselli, Tommaso Innocenti, Erica Nicola Lynch, Laura Parisio, Pasquale Apolito, Tommaso Mello, Giuseppe Macrì, Monica Milla, Maria Rosa Biagini, Mirko Tarocchi, Stefano Milani, Andrea Galli. Stevens–Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn’s Disease. Case Reports in Gastrointestinal Medicine 2020; 2020 doi: 10.1155/2020/3875024
|